Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines for sale...(nd to expand manufacturing and commercia...),Health

Date:2/26/2009

nd to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended September 30, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Ex
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
2. Angiotech To Participate In The American Academy Of Ophthalmology (AAO) 2007 Annual Meeting
3. Angiotech to participate in CIBC 18th Annual Healthcare Conference
4. Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
5. Boston University School of Medicine receives grant
6. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
7. Pharmacyclics Receives Nasdaq Notification
8. ING Run For Something Better Receives Healthy Youth for a Healthy Future Champion Award
9. International Partnership for Microbicides Receives US $130 Million from UK Government and the Gates Foundation
10. Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)